Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies

Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor

Salvatore Siena, Marco Bregni, Bruno Brando et al. · Blood · 1989 · 537 citations

Life Sciences, Hematology, Immunology +16

Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

Frankie A. Holmes, Joyce O’Shaughnessy, S. Vukelja et al. · Journal of Clinical Oncology · 2002 · 517 citations

Medicine, Oncology, Pharmacology +17

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

Graham Molineux, Olaf Kinstler, Bob Briddell et al. · Experimental Hematology · 1999 · 243 citations

Pharmacy, Pharmacology, Cell Therapy +1

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia

Yean Kee Lee, Nancy D. Bone, Ann K. Strege et al. · Blood · 2004 · 209 citations

Life Sciences, Cell Biology, Pharmacology +16

Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma

Julie Vose, Michael Crump, H M Lazarus et al. · Journal of Clinical Oncology · 2003 · 187 citations

Medicine, Oncology, Pharmacokinetics +16